|
|
|
|
|
|
|
30.05.25 - 13:03
|
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience (Business Wire)
|
|
|
David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025
Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition periodDENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effective May 30, 2025. Dan Giordano, Vice President of Finance for TriSalus, will serve as acting Chief Financial Officer during the transition period. Mr. Young remains available to the Company to support an orderly transition.
“We are thrilled to welcome David to our leadership team,” said Mar...
|
|
|
17.04.25 - 14:21
|
Vertiv to Participate in Upcoming Conferences (PR Newswire)
|
|
|
COLUMBUS, Ohio, April 17, 2025 /PRNewswire/ -- Vertiv Holdings Co. (NYSE: VRT), a global provider of critical digital infrastructure and continuity solutions, today announced its participation in two upcoming investor conferences in May. Giordano Albertazzi, Chief Executive Officer, and......
|
|
|
14.04.25 - 16:21
|
UBS Hires Financial Advisor Ryan Stevens in Billings, MT (Business Wire)
|
|
|
BILLINGS, Mont.--(BUSINESS WIRE)--UBS Wealth Management USA today announced that Ryan Stevens has joined the firm as a Financial Advisor in the Billings office. Ryan will be joining Montana Wealth Advisors, a nine-person team responsible for managing over $1.5 billion in client assets. Ryan joins the firm's Pacific Northwest Market, led by Market Executive Rob Giordano and Market Director Joe Hertig.
“As a longstanding advisor in the Billings area, Ryan works with many successful families, executives and business owners in the region,” said Joe Hertig, UBS Market Director of Montana. “He will be an important addition to Montana Wealth Advisors as they continue to grow their business and depth of expertise.”
“Ryan is a great addition to our wealth management team supporting the Billings community,” said Rob Giordano, Market Executive for the Pacific Northwest Market. “His dedication, experience and client focus position him well for continued growth and success in the years ahead.”
Ryan St...
|
|
|
27.03.25 - 17:18
|
UBS Hires Financial Advisor Amani Harris in Seattle, WA (Business Wire)
|
|
|
SEATTLE--(BUSINESS WIRE)--UBS Wealth Management USA today announced that Amani Y. Harris has joined the firm as a First Vice President and Portfolio Manager in the Seattle office. Amani joins the firm's Pacific Northwest Market, led by Market Executive Rob Giordano and Associate Market Executive Kevin Janke.
“As a longstanding advisor in the Seattle area, Amani works with many successful families, executives and business owners in the region and across the US,” said Kevin Janke, UBS Pacific Northwest Associate Market Executive. “He and his team have deep expertise in guiding clients through all aspects of the financial planning process.”
“Amani is a great addition to our wealth management team supporting the Seattle community,” said Rob Giordano, Market Executive for the Pacific Northwest Market. “His dedication, experience and client focus position him well for continued growth and success in the years ahead.”
Amani Harris manages over $180 million in client assets for families and indiv...
|
|
|
11.03.25 - 12:03
|
Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire EN)
|
|
|
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date....
|
|
|
|
|
|
|
31.10.24 - 21:09
|
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire EN)
|
|
|
CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
